Phase 4 N=48 Santyl vs. Sharp Debridement of Diabetic Foot Wounds
Diabetic Foot Ulcers · Foot Wounds
Primary: Bates-Jensen Wound Assessment Score - Modified (BWAT-m) — 15.8; 13.8 units on a scale — p==0.208
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=73 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
Hemophilia A
Primary: Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens — 1.61; 1.46 (bleeds/year)^(1/2) — p=0.6016
Phase 4 N=26 Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
Pediculosis
Primary: Cmax for Spinosyn A — NA ng/mL
Phase 4 N=40 Steroid Free Immunosuppression in Liver Transplantation
Liver Cirrhosis · Liver Transplant Disorder
Primary: Graft Survival Rate — 100; 94.7; 90; 84 percentage of participants
Phase 4 N=38 Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
Coronary Artery Disease · Type 2 Diabetes Mellitus
Primary: Plasminogen Activator Inhibitor 1 — 0.65; 3.82 ng/ml
Phase 4 N=32 Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
HIV Infections · Hyperlipidemia
Primary: Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval — 1.09; 1.59; 1.75 ng*hr/ml — p=0.43
Phase 4 N=40 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression
Binge Eating · Depression
Primary: Binge Eating Days — 4.3; 3.8 Mean Number of days — p=<0.05
Phase 4 N=660 Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
Chronic Obstructive Pulmonary Disease, COPD
Primary: Forced Expiratory Volume in 1 Second (FEV1) Pre-dose — 0.064; -0.001 Liters
Phase 4 N=311 Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
Asthma
Primary: Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) Averaged Over Treatment Period — 0.16; 0.07 Liters
Phase 4 N=31 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
Age-Related Maculopathy · Choroidal Neovascularization
Primary: Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months — 5.9; 7.6; 16.4 Letters
Phase 4 N=566 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001
Phase 4 N=310 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
Phase 4 N=350 A Trial of Oral Misoprostol for Labor Augmentation
Labor Augmentation
Primary: Uterine Tachysystole — 50; 41 participants
Phase 4 N=164 Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Conjunctival Hyperemia at Week 12 — 0.42; 0.46; 0.44 Score on a scale
Phase 4 N=273 Acceptability of the NuvaRing Among Students
Birth Control Compliance
Primary: Adherence Rate (Rate of Perfect Method Use) — 57; 45 Percentage of Participants — p=0.05